IDH1 and IDH2 Mutation Analysis
Comprehensive Genetic Testing for Brain Tumor Diagnosis
The IDH1 and IDH2 Mutation Analysis represents a breakthrough in molecular diagnostics for brain tumor patients. This advanced genetic test specifically targets mutations in the isocitrate dehydrogenase 1 and 2 genes, which play a crucial role in cellular metabolism and have been identified as key biomarkers in various central nervous system tumors, particularly gliomas.
What Does This Test Measure?
This specialized analysis detects specific genetic alterations in the IDH1 and IDH2 genes using the highly accurate Sanger Sequencing method. The test identifies:
- Point mutations in the IDH1 gene at codon R132
- Mutations in the IDH2 gene at codons R172 and R140
- Specific amino acid substitutions that affect enzyme function
- Genetic changes that influence tumor metabolism and growth patterns
Who Should Consider This Test?
This genetic analysis is particularly important for individuals experiencing:
- Persistent headaches that don’t respond to conventional treatment
- Unexplained seizures or neurological symptoms
- Cognitive changes, memory problems, or personality alterations
- Vision changes, speech difficulties, or motor function impairment
- Patients with suspected or diagnosed glioma tumors
- Individuals with family history of brain tumors
- Patients requiring precise tumor classification for treatment planning
Clinical Benefits of IDH1/IDH2 Testing
Undergoing this genetic analysis provides numerous advantages for patient care:
- Accurate Diagnosis: Helps distinguish between different types of brain tumors
- Prognostic Information: IDH-mutated tumors often have better outcomes
- Treatment Guidance: Informs targeted therapy decisions
- Surgical Planning: Assists neurosurgeons in determining resection margins
- Clinical Trial Eligibility: Opens access to targeted therapy trials
- Long-term Monitoring: Provides baseline for future treatment response assessment
Understanding Your Test Results
Your genetic test results will fall into one of several categories:
- IDH Mutation Detected: Indicates the presence of specific genetic changes associated with certain glioma subtypes. This finding often correlates with better response to treatment and improved prognosis.
- No Mutation Detected: Suggests the tumor may be a different subtype requiring alternative treatment approaches.
- Inconclusive Results: May require additional testing or sample collection.
It’s essential to discuss your results with your healthcare provider, who can interpret them in the context of your specific medical situation and develop an appropriate treatment plan.
Test Information and Pricing
| Test Component | Details |
|---|---|
| Test Name | IDH1 and IDH2 Mutation Analysis |
| Regular Price | $400 USD |
| Discount Price | $300 USD |
| Turnaround Time | 7-8 days |
| Sample Type | Tumor Tissue (Paraffin embedded tissue blocks) |
| Testing Method | Sanger Sequencing |
Pre-Test Instructions
The IDH1 and IDH2 Mutation Analysis requires a Doctor’s prescription for testing. Please note that prescriptions are not applicable for surgery and pregnancy cases or individuals planning to travel abroad. Our genetic counseling team is available to discuss any questions you may have about the testing process.
Nationwide Accessibility
We have diagnostic centers conveniently located across the United States, serving major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our state-of-the-art facilities ensure consistent, high-quality testing standards nationwide.
Take Action for Your Health
Don’t wait to get the answers you need for proper diagnosis and treatment planning. Early genetic testing can make a significant difference in your treatment journey. Our experienced team is ready to assist you with scheduling, sample collection, and result interpretation.
Call us today at +1(267) 388-9828 to book your IDH1 and IDH2 Mutation Analysis or to speak with our genetic specialists about your testing needs.
